Back to Report Store Home

Generic Growth Strategies - Market Driven by Impending Patent Cliff, Declining R&D Productivity and Government Initiatives to Reduce Healthcare Costs

  • Published: Dec-2012
  • Report Code: GBIHC263MR
  • Report Format: pdf

Description

List of Tables

Table 1: Generic Growth Strategies, Global, Revenues of Leading Generic Companies ($bn), 2010–2011

Table 2: Generic Growth Strategies, Global, Revenues of Major Drugs Due for Patent Expiry ($m), 2013–2020

Table 3: Generic Growth Strategies, Number of Generic ANDA Filed and Approvals, 2006–2011

Table 4: Generic Growth Strategies, ANDA Approvals by Month, The US, 2011–2012

Table 5: Generic Growth Strategies, Number of EMA Authorized Generics, Europe, 2007–2012

Table 6: Generic Growth Strategies, Number of Biosimilars Authorized by the EMA, Europe, 2006–2012

Table 7: Generic Growth Strategies, The US, Generic Drug Cost-Sharing (%), 2011–2020

Table 8: Generic Growth Strategies, Notable Authorized Generics Entry, The US, 2010–2012

Table 9: Generic Growth Strategies, Generic Products Launched, Teva, The US, 2011

Table 10: Generic Growth Strategies, Top Five Generic Active Ingredients, STADA Group, Revenue ($m), 2011

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$3500
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$7000
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$10500
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards